Use of Mutational Analysis to Help Decide Whether Patients with Myelodsysplastic Syndromes Should Receive Allogeneic Hematopoietic Cell Transplant

This podcast will use the study reported by Bejar and colleagues to review the role of screening for TET2, DNMT3A, and particularly TP53, mutations in deciding whether to recommend allogeneic hematopoietic cell transplant for patients with myelodysplastic syndromes.